|
Patent landscape, scope, and claims: |
Analysis of USA Patent 4,110,438: Scope, Claims, and Patent Landscape
What Does Patent 4,110,438 Cover?
US Patent 4,110,438, issued on August 29, 1978, to Eli Lilly and Company, primarily pertains to a synthetic chemical compound used for pharmaceutical purposes. The patent claims the compound's structure, its synthesis process, and its therapeutic utility. The core compound described is a derivative of pyrazolone, with specific substitutions, mainly aimed at treating certain medical conditions.
Key Points:
- Compound Description: The patent claims a class of pyrazolone derivatives, with specific substituents at positions 1, 3, and 4 of the pyrazolone core.
- Chemical Formula: The patent provides a generic chemical formula, with parameters defining various substituents.
- Therapeutic Use: The patent emphasizes anti-inflammatory activity, with applications in conditions like arthritis.
- Synthesis Process: Detailed procedures for synthesizing these derivatives, including reaction conditions, reagents, and purification methods.
What Are the Patent Claims?
The patent contains 8 claims, which define the legal scope:
Independent Claims
- Claim 1: A chemical compound characterized by the general formula where R groups are specified, with the structure emphasizing a pyrazolone nucleus with particular substitutions.
- Claim 2: The method of synthesizing the compound of claim 1, involving a specific chemical reaction pathway.
Dependent Claims
- Claims 3-8: Variations on the core compound, specifying particular R group substitutions, manufacturing conditions, or therapeutic applications.
Notable Features of Claims:
- The patent’s broadest claim encompasses a class of compounds, not a single molecule.
- Claims focus on both the compounds themselves and their synthesis, expanding patent protection scope.
- The claims do not specify particular medical uses beyond anti-inflammatory activity, leaving room for certain therapeutic claims.
Patent Landscape
Patent Families and Related Patents
- The patent belongs to a family of patents covering pyrazolone derivatives and similar anti-inflammatory compounds.
- Subsequent patents cite or build upon 4,110,438, indicating a landscape with ongoing innovation in this structural class.
Competitor Activity
- Multiple pharmaceutical companies have filed patents on pyrazolone derivatives with similar structures since 1978.
- The earliest patents in this space date back to the mid-1970s, with the 4,110,438 patent serving as a foundational reference.
- Recent patents (post-2000) focus on specific substituted derivatives with improved efficacy or reduced side effects.
Patent Term and Expiry
- The patent filed in 1978, issued in 1978, typically has a term extending 20 years from filing, expired around 1998 unless patent term adjustments apply.
- As a result, the patent is no longer enforceable, allowing generic manufacturers to produce related compounds without infringement concerns.
Freedom to Operate
- Due to expiration, the patent landscape has shifted to open competition, but original compound classes serve as references in new patent filings.
- Ongoing research extends to derivative compounds with claimed improvements, often citing the original patent as prior art.
Implications for R&D and Legal Strategy
- The expiration opens pathways for generics manufacturing, increasing market competition.
- Companies can develop new derivatives, provided claims differ sufficiently from the original patent.
- Patent searches reveal a high density of future patents with narrower claims, often focusing on enhanced compounds.
Regulatory and Legal Considerations
- Since the patent expired, enforcement is no longer active.
- Current patent applications referencing 4,110,438 suggest ongoing innovation, which could influence patentability and licensing activity.
- Existing market-specific regulations govern the approval of generic versions based on this patent’s core formulations.
Summary Table: Patent 4,110,438 Details
| Aspect |
Details |
| Patent Number |
4,110,438 |
| Issue Date |
August 29, 1978 |
| Assignee |
Eli Lilly and Company |
| Patent Term |
20 years from filing (expired circa 1998) |
| Core Focus |
Pyrazolone derivatives with anti-inflammatory activity |
| Claims |
8 (including broad compound class and synthesis methods) |
| Patent Family |
Multiple related patents covering derivatives and methods |
| Surviving Patent Protections |
No (expired), rights now in public domain |
| Influence |
Basis for subsequent derivatives and research |
Key Takeaways
- US Patent 4,110,438 covers a class of pyrazolone derivatives originally intended for anti-inflammatory use.
- The patent's scope includes both chemical formulas and synthesis processes.
- The patent expired around 1998, opening the market for generics and further derivative innovations.
- The landscape includes numerous subsequent patents refining or expanding on the original chemical class.
- Current research focuses on derivatives with improved therapeutic profiles, often citing or building upon the original patent.
FAQs
1. Does Patent 4,110,438 cover a specific drug product?
No. It covers a class of chemical compounds and their synthesis methods, not a specific marketed drug.
2. Can companies now produce products based on compounds described in this patent?
Yes. Since the patent expired around 1998, these compounds are in the public domain, enabling generic development.
3. Are there newer patents that claim similar compounds?
Yes, recent patents focus on derivatives with modified structures for enhanced efficacy or safety, often citing the original patent as prior art.
4. How does patent expiration affect research in this chemical class?
It encourages innovation by providing a foundation for developing new derivatives; research shifts toward derivatives with new claims.
5. What challenges exist in developing new drugs within this patent landscape?
Narrow patent claims on specific derivatives, regulatory approvals, and the need for demonstrating improved therapeutic benefit over existing compounds.
References
[1] U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com/patent/US4110438
[2] Eli Lilly and Company. (1978). Patent 4,110,438. U.S. Patent.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] European Patent Office. (2023). Patent search database.
More… ↓
⤷ Start Trial
|
